options could be considered.” The current NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Hepatobiliary Cancers recommend resection as the primary treatment option in this setting; however, locoregional therapies are frequently used
Search Results
Presenters: Rajiv Agarwal and Lea K. Matsuoka
Moderator : Daniel B. Brown
Presenters: Shannon M. Ansbaugh, Gary Deng, Rev. George F. Handzo, and Karen L. Syrjala
Moderator : Jessica R. Bauman
the treatment they need and deserve.” Ms. Ansbaugh continues to navigate the effects of her medical journey on her mental health. She now serves as a patient advocate representative on the NCCN Clinical Practice Guidelines in Oncology (NCCN
Presenter: Shaji K. Kumar
regimen is definitely one to consider for patients with high-risk multiple myeloma, to obtain an MRD-negative state,” Dr. Kumar said. Dara-VRd, therefore, has been added to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Multiple
Presenter: Nancy L. Keating
produce a benefit,” Dr. Keating said. This understanding has led many recent guidelines to suggest stopping cancer screening when life expectancy is <10 years, she added. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Older Adult
Potjana Jitawatanarat, Arpita Desai, Pradeep Sharda, Hong Liu, Maureen Ross, Francisco J. Hernandez-llizaliturri, Philip L. McCarthy, and George L. Chen
confers the worst prognosis. Favorable risk factors include del(13q) and a lymphocyte doubling time that is greater than a year. The CLL section of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Hodgkin’s Lymphoma recommends
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
Featured Updates to the NCCN Guidelines
David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D’Amico, Thomas J. Dilling, Jonathan Dowell, Scott Gettinger, Matthew A. Gubens, Aparna Hegde, Mark Hennon, Rudy P. Lackner, Michael Lanuti, Ticiana A. Leal, Jules Lin, Billy W. Loo Jr, Christine M. Lovly, Renato G. Martins, Erminia Massarelli, Daniel Morgensztern, Thomas Ng, Gregory A. Otterson, Sandip P. Patel, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda Tam, Jane Yanagawa, Stephen C. Yang, Kristina M. Gregory, and Miranda Hughes
therapies, immunotherapies, and their respective biomarkers for eligible patients with NSCLC. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for NSCLC address all aspects of management for NSCLC. For the 2020 and 2021 updates, several
David S. Ettinger, Wallace Akerley, Hossein Borghaei, Andrew C. Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D'Amico, Todd L. Demmy, Ramaswamy Govindan, Frederic W. Grannis Jr, Stefan C. Grant, Leora Horn, Thierry M. Jahan, Ritsuko Komaki, Feng-Ming (Spring) Kong, Mark G. Kris, Lee M. Krug, Rudy P. Lackner, Inga T. Lennes, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Mary C. Pinder-Schenck, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, Theresa A. Shapiro, Scott J. Swanson, Kurt Tauer, Douglas E. Wood, Stephen C. Yang, Kristina Gregory, and Miranda Hughes
diesel fumes; see the NCCN Clinical Practice Guidelines in Oncology [NCCN Guidelines] for Lung Cancer Screening, available online at NCCN.org ). 1 , 4 , 12 , 13 NCCN Guidelines Insights : Non-Small Cell Lung Cancer, Version 2.2013 Version 2
Michael J. Berger, David S. Ettinger, Jonathan Aston, Sally Barbour, Jason Bergsbaken, Philip J. Bierman, Debra Brandt, Dawn E. Dolan, Georgiana Ellis, Eun Jeong Kim, Steve Kirkegaard, Dwight D. Kloth, Ruth Lagman, Dean Lim, Charles Loprinzi, Cynthia X. Ma, Victoria Maurer, Laura Boehnke Michaud, Lisle M. Nabell, Kim Noonan, Eric Roeland, Hope S. Rugo, Lee S. Schwartzberg, Bridget Scullion, John Timoney, Barbara Todaro, Susan G. Urba, Dorothy A. Shead, and Miranda Hughes
, 12 Although vomiting can often be prevented or substantially decreased by using prophylactic antiemetic regimens, nausea is much harder to control. 13 – 18 The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Antiemesis are
Kenneth C. Anderson, Melissa Alsina, Djordje Atanackovic, J. Sybil Biermann, Jason C. Chandler, Caitlin Costello, Benjamin Djulbegovic, Henry C. Fung, Cristina Gasparetto, Kelly Godby, Craig Hofmeister, Leona Holmberg, Sarah Holstein, Carol Ann Huff, Adetola Kassim, Amrita Y. Krishnan, Shaji K. Kumar, Michaela Liedtke, Matthew Lunning, Noopur Raje, Seema Singhal, Clayton Smith, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Donna Weber, Joachim Yahalom, Dorothy A. Shead, and Rashmi Kumar
along with SPEP and SIFE yields high sensitivity while screening for MM and related plasma cell disorders. 7 Therefore, this assay is now included as a part of the initial diagnostic workup in the NCCN Clinical Practice Guidelines in Oncology (NCCN
NCCN Guidelines and NCCN Compendium Updated NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer. These NCCN Guidelines are currently available as Version 1.2011. A footnote was
